Lipid abnormalities and cardiovascular risk in renal disease

Journal of the American Society of Nephrology

Volumn 19, Issue 6, 2008, Pages 1065-1070

  Ritz, Eberhard ^a,b,c   Wanner, Christoph ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c Nierenzentrum   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; EZETIMIBE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ALBUMINURIA; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DIALYSIS; DYSLIPIDEMIA; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; KIDNEY FAILURE; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; REVIEW; RHABDOMYOLYSIS; STROKE; TREATMENT INDICATION; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; METABOLISM; RISK FACTOR;

CARDIOVASCULAR DISEASES; CHRONIC DISEASE; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY DISEASES; RISK FACTORS;

EID: 48049123731     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2007101128     Document Type: Review

References (55)

1. Kaysen GA, de Sain-van der Velden MG: New insights into lipid metabolism in the nephrotic syndrome. Kidney Int 71[Suppl]: S18-S21, 1999
2. Krane V, Wanner C: The metabolic burden of diabetes and dyslipidaemia in chronic kidney disease. Nephrol Dial Transplant 17[Suppl 11]: 523-527, 2002
3. Ikewaki K, Schaefer JR, Frischmann ME, Okubo K, Hosoya T, Mochizuki S, Dieplinger B, Trenkwalder E, Schweer H, Kronenberg F, Koenig P, Dieplinger H: Delayed in vivo catabolism of intermediate-density lipoprotein and low-density lipoprotein in hemodialysis patients as potential cause of premature atherosclerosis. Arterioscler Thromb Vasc Biol 25: 2615-2622, 2005
4. Weintraub M, Burstein A, Rassin T, Liron M, Ringel Y, Cabili S, Blum M, Peer G, Laina A: Severe defect in clearing postprandial chylomicron remnants in dialysis patients. Kidney Int 42: 1247-1252, 1992
5. Lee DM, Knight-Gibson C, Samuelsson O, Attman PO, Wang CS, Alaupovic P: Lipoprotein particle abnormalities and the impaired lipolysis in renal insufficiency. Kidney Int 61: 209-218, 2002
6. Shoji T, Nishizawa Y, Kawagishi T, Kawasaki K, Taniwaki H, Tabata T, Inoue T, Morii H: Intermediate-density lipoprotein as an independent risk factor for aortic atherosclerosis in hemodialysis patients. J Am Soc Nephrol 9: 1277-1284, 1998
7. Quaschning T, Schömig M, Keller M, Thiery J, Nauck M, Schollmeyer P, Wanner C, Krämer-Guth A: Non-insulin-dependent diabetes mellitus and hypertriglyceridemia impair lipoprotein metabolism in chronic hemodialysis patients. J Am Soc Nephrol 10: 332-341, 1999
8. Rajman I, Harper L, McPake D, Kendall MJ, Wheeler DC: Low-density lipoprotein subfraction profiles in chronic renal failure. Nephrol Dial Transplant 13: 2281-2287, 1998
9. Kronenberg F, Kuen E, Ritz E, Junker R, König P, Kraatz G, Lhotta K, Mann JF, Müller GA, Neyer U, Riegel W, Reigler P, Schwenger V, Von Eckardstein A: Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure. J Am Soc Nephrol 11:105-115, 2000
10. Fishbane S, Bucala R, Pereira BJ, Founds H, Vlassara H: Reduction of plasma apolipoprotein-B by effective removal of circulating glycation derivatives in uremia. Kidney Int 52: 1645-1650, 1997
11. Karabina SA, Pappas H, Miltiadous G, Bairaktari E, Christides D, Tselepis A, Elisaf M, Siamopoulos K: Compositional lipoprotein changes and low-density lipoprotein susceptibility to oxidation in chronic renal failure patients with heavy proteinuria. Nephron Clin Pract 95: 77-83, 2003
12. Horkko S, Savolainen MJ, Kervinen K, Kesäniemi YA: Carbamylation-induced alterations in low-density lipoprotein metabolism. Kidney Int 41: 1175-1181, 1992
13. Königer M, Quaschning T, Wanner C, Schollmeyer P, Krämer-Guth A: Abnormalities in lipoprotein metabolism in hemodialysis patients. Kidney Int 71[Suppl]: S248-S250, 1999
14. Kronenberg F, Never U, Lhotta K, Trenkwalder E, Auinger M, Pribasnig A, Meisl T, König P, Dieplinger H: The low molecular weight apo(a) phenotype is an independent predictor for coronary artery disease in hemodialysis patients: a prospective follow-up. J Am Soc Nephrol 10: 1027-1036, 1999
15. Frischmann ME, Kronenberg F, Trenkwalder E, Schaefer JR, Schweer H, Dieplinger B, Koenig P, Ikewaki K, Dieplinger H: In vivo turnover study demonstrates diminished clearance of lipoprotein(a) in hemodialysis patients. Kidney Int 71: 1036-1043, 2007
16. Wanner C, Krane V: Uremia-specific alterations in lipid metabolism. Blood Purif 20: 451-453, 2002
17. Degoulet P, Legrain M, Réach I, Aimé F, Devriés C, Rojas P, Jacobs C: Mortality risk factors in patients treated by chronic hemodialysis: report of the Diaphane collaborative study. Nephron 31: 103-110, 1982
18. Lowrie EG, Lew NL: Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 15: 458-482, 1990
19. Kwan BC, Kronenberg F, Beddhu S, Cheung AK: Lipoprotein metabolism and lipid management in chronic kidney disease. J Am Soc Nephrol 18: 1246-1261, 2007
20. Nishizawa Y, Shoji T, Kakiya R, Tsujimoto Y, Tabata T, lshimura E, Nakatani T, Miki T, lnaba M: Non-high-density lipoprotein cholesterol (non-HDL-C) as a predictor of cardiovascular mortality in patients with endstage renal disease. Kidney Int 75[Suppl], S117-S120, 2003
21. Kalantar-Zadeh K, Stenvinkel P, Pillon L, Kopple JD: Inflammation and nutrition in renal insufficiency. Adv Ren Replace Ther 10: 155-169, 2003
22. Liu Y, Coresh J, Eustace JA, Longenecker JC, Jaar B, Fink NE, Tracy RP, Powe NR, Klag MJ: Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA 291: 451-459, 2004
23. Hyre AD, Fox CS, Astor BC, Cohen AJ, Muntner P: The impact of reclassifying moderate CKD as a coronary heart disease risk equivalent on the number of US adults recommended lipid-lowering treatment. Am J Kidney Dis 49: 37-45, 2007
24. Tonelli M. Should CKD be a coronary heart disease risk equivalent? Am J Kidney Dis 49: 8-11, 2007
25. Sanfelippo ML, Swenson RS, Reaven GM: Reduction of plasma triglycerides by diet in subjects with chronic renal failure. Kidney Int 11: 54-61, 1977
26. Ando M, Sanaka T, Nihei H: Eicosapentanoic acid reduces plasma levels of remnant lipoproteins and prevents in vivo peroxidation of LDL in dialysis patients. J Am Soc Nephrol 10: 2177-2184, 1999
27. Keane WF, Kasiske BL, O'Donnell MP, Kim Y: The role of altered lipid metabolism in the progression of renal disease: experimental evidence. Am J Kidney Dis 17[Suppl 1]: S38-S42, 1991
28. Wheeler DC: Lipids: what is the evidence for their role in progressive renal disease? Nephrol Dial Transplant 10: 14-16, 1995
29. Olbricht CJ, Wanner C, Thiery J, Basten A: Simvastatin in nephrotic syndrome: Simvastatin in Nephrotic Syndrome Study Group. Kidney Int 71 [Suppl]: S113-S116, 1999
30. Sandhu S, Wiebe N, Fried LF, Tonelli M: Stalins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol 17: 2006-2016, 2006
31. Tonelli M, Isles C, Curhan GC, Tonkin A, Pfeffer MA, Shepherd J, Sacks FM, Furberg C, Cobbe SM, Simes J, Craven T, West M: Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 110: 1557-1563, 2004
32. Tonelli M, Isles C, Curhan GC, Tonkin A, Pfeffer MA, Sheperd J, Sacks FM, Furberg C, Cobbe SM, Simes J, Craven T, West M: Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation 112: 171-178, 2005
33. Holdaas H, Fellström B, Jardine AG, Holme I, Nyberg G, Fauchald P, Grönhagen-Riska C, Madsen S, Neumayer HH, Cole E, Maes B, Ambühl P, Olsson AG, Hartmann A, Solbu DO, Pedersen TR; Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators: Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 361: 2024-2031, 2003
34. Holdaas H, Fellström B, Cole E, Nyberg G, Olsson AG, Pedersen TR, Madsen S, Grönhagen-Riska C, Neumayer HH, Maes B, Ambühl P, Hartmann A, Staffier B, Jardine AG; Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators: Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. Am J Transplant 5: 2929-2936, 2005
35. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J; ASCOT investigators: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361: 1149-1158, 2003
36. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebocontrolled trial. Lancet 360: 7-22, 2002
37. Chonchol M, Cook T, Kjekshus J, Pedersen TR, Lindenfeld J: Simvastatin for secondary prevention of all-cause mortality and major coronary events in patients with mild chronic renal insufficiency. Am J Kidney Dis 49: 373-382, 2007
38. Schaeffner ES, Kurth T, Curhan GC, Glynn RJ, Rexrode KM, Baigent C, Buring JE, Gaziano JM: Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol 14: 2084-2091, 2003
39. Tonelli M: Do statins protect the kidney as well as the heart? Nephrol Dial Transplant 21: 3005-3006, 2006
40. Seliger SL, Weiss NS, Gillen DL, Kestenbaum B, Ball A, Sherrard DJ, Stehman-Breen CO: HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int 61: 297-304, 2002
41. Holmberg B, Brännström M, Bucht B, Crougneau V, Dimeny E, Ekspong A, Granroth B, Gröntoft KC, Hadimeri H, Ingman B lsaksson B, Johansson G, Lindberger K, Lundberg L, Mikaelsson L, Olausson E, Persson B, Welin D, Wikdahl AM, Stegmayr BG: Safety and efficacy of atorvastatin in patients with severe renal dysfunction. Scand J Urol Nephrol 39: 503-510, 2005
42. Wanner C, Krane V, März W, Olschewski M, Mann JF, Ruf G, Ritz E; German Diabetes and Dialysis Study Investigators: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353: 238-248, 2005
43. Lindner A, Charra B, Sherrard DJ, Scribner BH: Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 290: 697-701, 1974
44. Buzello M, Törnig J, Faulhaber J, Ehmke H, Ritz E, Amann K: The apolipoprotein e knockout mouse: a model documenting accelerated atherogenesis in uremia. J Am Soc Nephrol 14: 311-316, 2003
45. Fathi R, lsbel N, Short L, Haluska B, Johnson D, Marwick TH: The effect of long-term aggressive lipid lowering on ischemic and atherosclerotic burden in patients with chronic kidney disease. Am J Kidney Dis 43: 45-52, 2004
46. Schwarz U, Buzello M, Ritz E, Stein G, Raabe G, Wiest G, Mall G, Amann K: Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant 15: 218-223, 2000
47. Gross ML, Meyer HP, Ziebart H, Rieger P, Wenzel U, Amann K, Berger I, Adamczak M, Schirmacher P, Ritz E: Calcification of coronary intima and media: immunohistochemistry, backscatter imaging, and x-ray analysis in renal and nonrenal patients. Clin J Am Soc Nephrol 2: 121-134, 2007
48. Burke AP, Farb A, Malcom GT, Liang YH, Smialek J, Virmani R: Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med 336: 1276-1282, 1997
49. Roberts CG, E. Guallar, A. Rodriguez: Efficacy and safety of statin monotherapy in older adults: a meta-analysis. J Gerontol A Biol Sci Med Sci 62: 879-887, 2007
50. Colivicchi F, Bassi A, Santini M, Caltagirone C: Discontinuation of statin therapy and clinical outcome after ischemic stroke. Stroke 38: 2652-2657, 2007
51. Fellström B, Zannad F, Schmieder R, Holdaas H, Jardine A, Rose H, Wilpshaar W; AURORA Study Group: Effect of rosuvastatin on outcomes in chronic haemodialysis patients: design and rationale of the AURORA study. Curr Control Trials Cardiovasc Med 6: 9, 2005
52. Baigent C, Landry M: Study of Heart and Renal Protection (SHARP). Kidney Int 84[Suppl]: S207-S210, 2004
53. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296-1305, 2004
54. Van Biesen W, De Bacquer D, Verbeke F, Delanghe J, Lameire N, Vanholder R: The glomerular filtration rate in an apparently healthy population and its relation with cardiovascular mortality during 10 years. Eur Heart J 28: 478-483, 2007
55. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R; Cholesterol Treatment Trialists' (CTT) Collaborators: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366: 1267-1278, 2005